Rallybio Corp (RLYB): R&D Expense
$19.60M
Year ended 2025-12-31
$11.43M
Trailing 12 months to 2026-06-30
-21.6%
3-year compound annual growth
+2.1%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.60M | -52.8% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $41.51M | -22.5% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $53.54M | +31.6% | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $40.69M | +51.2% | 2024-03-12, From 2022-01-01 |
| 2021-12-31 | $26.91M | +52.6% | 2023-03-06, From 2021-01-01 |
| 2020-12-31 | $17.63M | n/a | 2022-03-15, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Rallybio Corp (RLYB) | 2025-12-31 | $19.60M | -52.8% |
| Onconetix, Inc. (ONCO) | 2024-12-31 | $154.4K | -92.1% |
| Hyperion Defi, Inc. (HYPD) | 2025-12-31 | $1.91M | -86.8% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $12.82M | +207.5% |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $35.27M | -47.5% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $2.11M | -57.8% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $5.52M | -61.4% |
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $8.24M | +249.0% |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $30.25M | -0.6% |
Compare RLYB, ONCO, HYPD, RFL side by side · Screen every company in Pharmaceutical Preparations ↗